Innoviva, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
INVA Nasdaq 2830 www.inva.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Innoviva, Inc.

Innoviva to Participate in Upcoming Investor Conferences - Jun 1st, 2026 9:00 am
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More - May 29th, 2026 4:55 pm
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - May 13th, 2026 2:30 pm
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness? - May 11th, 2026 4:08 am
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength - May 8th, 2026 3:01 pm
Innoviva (INVA) Tops Q1 Earnings Estimates - May 6th, 2026 7:45 pm
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress - May 6th, 2026 2:05 pm
3 Bargain-Cheap Small Caps Worth a Second Look - Apr 9th, 2026 6:24 am
Beacon Biosignals Upsizes Series B Financing to Over $97 Million - Apr 6th, 2026 4:30 am
Analysts See This Pharma Stock Surging 60%; Eyes Fresh Entry - Apr 2nd, 2026 12:03 pm
Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains - Mar 24th, 2026 2:06 am
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up - Mar 23rd, 2026 2:05 pm
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - Mar 23rd, 2026 11:37 am
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report - Mar 10th, 2026 4:30 am
Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 – Here’s Why - Mar 1st, 2026 2:27 am
Is It Time To Reassess Innoviva (INVA) After Its Strong Multi Year Share Price Run - Feb 28th, 2026 9:15 pm
Innoviva, Inc. (INVA): A Bull Case Theory - Feb 28th, 2026 6:26 am
Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference - Feb 28th, 2026 4:45 am
Celldex Therapeutics Stock Earns 88 RS Rating - Feb 26th, 2026 11:48 am
Nurix Therapeutics Stock Sees RS Rating Jump To 82 - Feb 25th, 2026 6:17 pm